• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Saturday, March 25, 2023
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Rheumatology community applauds CMS’s decision to scrap Part B payment demo

Bioengineer by Bioengineer
December 16, 2016
in Science News
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

ATLANTA – – The American College of Rheumatology (ACR) today applauded the decision from the Centers for Medicare & Medicaid Services (CMS) not to go forward with the agency's controversial Part B payment proposal, noting that the hard-fought outcome is good news for rheumatology patients who rely on Medicare Part B to access life-saving biologic therapies.

"We thank CMS for listening to the rheumatology community's concerns about the negative and disproportionate impact this proposal would have on our Medicare patients living with rheumatic diseases by not moving forward with this Part B Demonstration Project," said Dr. Sharad Lakhanpal, MBBS, MD, President of the ACR. "For older Americans living with painful and debilitating diseases like rheumatoid arthritis, lupus, spondyloarthritis, and psoriatic arthritis, safe access to biologic therapies is not an option but a necessity – which is why the ACR has been vocal in expressing our concerns about the unintended consequences of this proposal and its flawed cost-savings premise. This positive outcome will help ensure Medicare beneficiaries living with rheumatic diseases are able to continue receiving the therapies they need to manage their chronic conditions and avoid pain and disability."

From the time it was proposed in March 2016, the ACR has voiced strong opposition to the proposed rule. In detailed comments submitted to CMS earlier this year, the ACR expressed concerns about the lack of less expensive yet clinically equivalent biologic therapy options in the marketplace for Medicare patients living with rheumatic diseases, as well as the safety and health dangers posed by switching from a biologic therapy that works well for the patient.

The ACR has also noted that many rheumatologists – particularly small or rural practices that lack the ability to negotiate bulk discounts with pharmaceutical companies – have already been forced to stop administering biologic therapies to Medicare patients because the current Part B payment structure does not cover the costs of obtaining and providing these complex therapies in the outpatient setting. If the additional payment cuts proposed by CMS in the Part B Demonstration Project were to go through, the ACR warned that many rheumatology patients would be forced into less safe or more expensive settings to receive needed therapies, if these patients were able to receive them at all.

More than 52.5 million people – one in five Americans – live with rheumatic diseases, according to the Centers for Disease Control and Prevention (CDC). Rheumatic diseases are the nation's leading cause of disability, contributing more than $128 billion in costs to the U.S. healthcare system each year.

###

The American College of Rheumatology provides education, research, advocacy and practice management support to more than 6,400 U.S. rheumatologists and rheumatology health professionals. In doing so, the ACR advocates for high-value, high-quality healthcare policies and reforms that will ensure safe, effective, affordable and accessible rheumatology care. For more information, visit http://www.rheumatology.org.

Media Contact

Jocelyn Givens
[email protected]
229-220-6524
@ACRheum

http://www.rheumatology.org

############

Story Source: Materials provided by Scienmag

Share12Tweet7Share2ShareShareShare1

Related Posts

Picture1.png

Is early rhythm control in atrial fibrillation care cost-effective?

March 25, 2023
Transitions of low and high-entropy metal tellurides.

“Glassiness” and “blurriness” might explain the behavior of high-entropy superconductors

March 25, 2023

Illinois Tech Assistant Professor Ren Wang receives prestigious National Science Foundation Award

March 24, 2023

New type of entanglement lets scientists ‘see’ inside nuclei

March 24, 2023
Please login to join discussion

POPULAR NEWS

  • ChatPandaGPT

    Insilico Medicine brings AI-powered “ChatPandaGPT” to its target discovery platform

    65 shares
    Share 26 Tweet 16
  • Northern and southern resident orcas hunt differently, which may help explain the decline of southern orcas

    44 shares
    Share 18 Tweet 11
  • Skipping breakfast may compromise the immune system

    43 shares
    Share 17 Tweet 11
  • Insular dwarfs and giants more likely to go extinct

    35 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Is early rhythm control in atrial fibrillation care cost-effective?

“Glassiness” and “blurriness” might explain the behavior of high-entropy superconductors

Illinois Tech Assistant Professor Ren Wang receives prestigious National Science Foundation Award

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 48 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In